The Future of GLP-1 Pills for Weight Loss

Eli Lilly is a major player in the field of GLP-1 agonists, a class of drugs that have revolutionized weight loss and diabetes management. While their injectable GLP-1 medications like Zepbound (tirzepatide) have seen significant success, the company is now at the forefront of a new wave of innovation: oral GLP-1 pills.

Eli Lilly's Oral GLP-1: Orforglipron

Eli Lilly's investigational oral GLP-1 drug is called orforglipron. It is a once-daily, non-peptide small molecule that acts as a GLP-1 receptor agonist. This is a significant innovation because, unlike other GLP-1s, orforglipron is not a peptide, which can be more difficult to formulate as a pill due to digestion. Its small molecule structure allows it to be taken orally without restrictions on food and water.

Recent Phase 3 clinical trial results have been very promising for orforglipron:

Weight Loss Efficacy: In trials for adults with obesity, orforglipron has shown clinically meaningful weight loss. In one pivotal trial, participants on the highest dose lost an average of 12.4% (27.3 lbs) of their body weight over 72 weeks.

Cardiometabolic Benefits: Beyond weight loss, the drug has also shown improvements in cardiovascular risk factors, including non-HDL cholesterol, triglycerides, and systolic blood pressure.

Safety Profile: The safety and tolerability profile of orforglipron has been consistent with that of injectable GLP-1 therapies, with the most common side effects being gastrointestinal-related.

Regulatory Timeline: With the successful completion of Phase 3 trials, Eli Lilly is on track to submit orforglipron for regulatory approval to global agencies by the end of 2025. If approved, it could be available to patients by late 2026 or early 2027.

The Future of GLP-1 Pills for Weight Loss

The development of effective GLP-1 pills represents a major shift in the weight loss and obesity treatment landscape. Here's why this innovation is so significant and what it means for the future:

Increased Accessibility and Patient Choice: A once-daily pill offers a more convenient and discreet alternative to weekly injections. This could be a game-changer for people with needle anxiety or for whom the injection format is a barrier to treatment. The pill format also simplifies storage and travel.

Addressing Supply Constraints: The demand for injectable GLP-1s has often outpaced supply, leading to shortages. Eli Lilly has stated its confidence in its ability to manufacture and launch orforglipron "at scale," which could help alleviate some of these supply issues and make treatment more widely available.

The Chronic Disease Model: GLP-1 drugs are increasingly being viewed as long-term therapies for a chronic disease. The convenience of a pill may encourage greater adherence to long-term treatment, helping patients sustain their weight loss and manage related health conditions.

Expanding Indications: As research continues, GLP-1 drugs are showing promise for a range of health conditions beyond diabetes and weight loss, including cardiovascular disease, kidney disease, sleep apnea, and potentially even neurological conditions like Alzheimer's. The development of oral forms will likely accelerate this trend, as the convenience of a pill makes them more suitable for long-term use across a wider patient population.

Competition and Continued Innovation: Eli Lilly is not the only company in the oral GLP-1 space.

Other pharmaceutical companies are also developing similar drugs, which will drive further innovation and potentially lead to new formulations, greater efficacy, and improved side effect profiles.

In summary, Eli Lilly's work on orforglipron highlights a critical leap in the field of weight loss medicine. By transitioning from injectables to a daily pill, the company is not only providing a more patient-friendly option but also helping to expand access, redefine the treatment of obesity as a chronic condition, and shape the future of medicine.

To discuss how Nelson Advisors can help your HealthTech, MedTech or PharmaTech company, please email [email protected]